专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

KR1020160091435A PTP1B 연관 질병의 치료용 아미노스테로이드 审中-实审
标题翻译：用于治疗PTP1B相关疾病的氨基酸酯
公开(公告)号：KR1020160091435A
公开(公告)日：2016-08-02
申请号：KR1020167019758
申请日：2013-04-19
申请人： 오에이치알 파마서티컬, 인코포레이티드
发明人： 맥클래인,마이클 , 뤼츠-화이트,이네즈 , 말로이,더블유.리 , 울프,헨리알.
IPC分类号： C07J41/00 , A61K31/575
CPC分类号： C07J41/0005 , C07J41/005 , C07J41/0055 , C07J43/003 , C07J41/00 , A61K31/575 , Y10S514/843
摘要： 본발명은당뇨병치료를위한포유류내의 PTP1B 효소의선택적억제를위한아미노스테로이드화합물의사용에관한것이다.

2. 发明公开

KR1020010031370A 변형된 비타민 Ｋ-의존성 폴리펩티드 无效
标题翻译：修饰的维生素K依赖性多肽
公开(公告)号：KR1020010031370A
公开(公告)日：2001-04-16
申请号：KR1020007004378
申请日：1998-10-20
申请人： 미네소타대학리전트
发明人： 넬세스투엔개리엘
IPC分类号： C12N15/55
CPC分类号： C12N9/6437 , A61K38/00 , C07K2319/00 , C12N9/644 , C12N9/6464 , C12N9/647 , C12Y304/21021 , C12Y304/21022 , C12Y304/21069 , Y10S514/843
摘要： 본발명은향상된막 결합친화성을가진비타민 K-의존성폴리펩티드를제공한다. 이들폴리펩티드는포유동물에서응혈의형성을조절하기위한목적으로사용될수 있다. 또한, 응혈의형성을조절하는방법에대해설명하고있다.

3. 发明公开

KR1020010012149A 임신 방지용 축합 중합체 조성물 失效
标题翻译：用于预防孕妇的凝结聚合物组合物
公开(公告)号：KR1020010012149A
公开(公告)日：2001-02-15
申请号：KR1019997010094
申请日：1998-04-27
申请人： 프로셉트, 인코포레이티드
发明人： 손데르판,앤드류,제이. , 프로피,앨버트,티. , 챈슬러,토니 , 매킨레이,마고
IPC分类号： A61K31/715
CPC分类号： A61K31/795 , Y10S514/841 , Y10S514/843
摘要： This invention pertains to the discovery that condensation polymers of an aldehyde and aromatic sulfonic acids and fractions thereof, such as formaldehyde naphthalenesulfonic acid condensation polymers, can prevent pregnancy in an individual.
摘要翻译：本发明涉及醛和芳族磺酸的缩聚物及其馏分如甲醛萘磺酸缩聚物可以预防个体怀孕的发现。

4. 发明授权

KR100221486B1 베타인 및 아민 옥사이드를 함유하는 약제 失效
标题翻译：含有BETAINE和氨氧化物的药物组合物
公开(公告)号：KR100221486B1
公开(公告)日：1999-09-15
申请号：KR1019910018612
申请日：1991-10-22
申请人： 이이 비이 마이클즈 리서어치 어소시에이츠 인코포레이팃드
发明人： 에드윈비이마이클즈 , 대니얼맬라머드
IPC分类号： A61K31/25
CPC分类号： A01N33/24 , A01N37/20 , A01N37/44 , A01N37/46 , A61K9/0034 , A61K31/14 , A61K31/185 , A61K31/195 , A61K31/205 , A61K31/415 , A61L2/0088 , A61L31/16 , A61L2300/204 , A61L2300/208 , A61L2300/408 , A61L2300/45 , A61L2300/452 , Y02A50/463 , Y10S514/843 , Y10S514/934 , A01N2300/00 , A61K2300/00 , A01N43/50 , A01N41/04 , A61K31/13 , A61K31/16
摘要： There is provided methods for inhibitng the activity of enveloped viruses, treatment of viral infections and method inactivating sperm. There is provided articles for use in these methods.

5. 发明授权

KR100567796B1 임신 방지용 축합 중합체 조성물 失效
标题翻译：用于预防孕妇的凝结聚合物组合物
公开(公告)号：KR100567796B1
公开(公告)日：2006-04-05
申请号：KR1019997010094
申请日：1998-04-27
申请人： 프로셉트, 인코포레이티드
发明人： 손데르판,앤드류,제이. , 프로피,앨버트,티. , 챈슬러,토니 , 매킨레이,마고
IPC分类号： A61K31/715
CPC分类号： A61K31/795 , Y10S514/841 , Y10S514/843
摘要： This invention pertains to the discovery that condensation polymers of an aldehyde and aromatic sulfonic acids and fractions thereof, such as formaldehyde naphthalenesulfonic acid condensation polymers, can prevent pregnancy in an individual.

6. 发明授权

KR100553292B1 메조프로게스틴11β-[4Ε-(히드록시이미노메틸)페닐]-17α-메톡시메틸-17β-메톡시-에스트라-4,9-디엔-3-온의 신규 고체 형태 失效
标题翻译：新型固体形式的中孕酮11β-[4E-羟基亚氨基甲基 - 苯基]-17β-甲氧基甲基-17β-甲氧基 - 雌-4,9-二烯-3-酮
公开(公告)号：KR100553292B1
公开(公告)日：2006-02-22
申请号：KR1020027015762
申请日：2001-05-09
申请人： 바이엘 파마 악티엔게젤샤프트
发明人： 그라베,데틀레프 , 회젤,페터 , 뮐러,우베 , 빈터,가브리엘레
IPC分类号： C07J41/00
CPC分类号： C07J41/00 , C07J41/0083 , Y10S514/843
摘要： Nonsolvated crystalline 11beta -(4-((E)-hydroxyiminomethyl)phenyl)-17 alpha -methoxymethyl-17beta -methoxy-4,9-estradien-3-one (I) is new. An independent claim is also included for a process for preparing (I). - ACTIVITY : Gynecological. - MECHANISM OF ACTION : Progesterone receptor ligand.

7. 发明公开

KR1020000023633A 배합된 약제학적 에스트로겐-안드로겐-프로제스틴 경구 피임약 无效
标题翻译：组合药物雌激素原-ORPOGESTIN口服合同
公开(公告)号：KR1020000023633A
公开(公告)日：2000-04-25
申请号：KR1019997000082
申请日：1997-07-09
申请人： 웨이크 포리스트 유니버시티
发明人： 제이요마누엘제이
IPC分类号： A61K31/565 , A61K31/57
CPC分类号： A61K31/565 , A61K31/57 , Y10S514/841 , Y10S514/843 , A61K2300/00
摘要： PURPOSE: Provided are methods and compositions for oral contraception. Certain compositions contain androgens, preferably methyltestosterone to be taken by younger users of the contraceptives to inhibit adverse effects of oral contraceptive use on bone mineral density. CONSTITUTION: Provided is a pharmaceutical preparation of contraceptives, which contain androgens, preferably methyltestosterone, progestin and estrogen to improves bone mineral density of users of the contraceptives. Contraceptive formulation uses more than three levels of androgen and androgen formulation is prescribed according to change of the level of testosterone in blood serum of user. In an aspect, a first composition containing methyltestosterone of 0.2-1.5mg, revonorgestral of 0.05mg, and ethynyl estradiol of 0.03mg in daily dosage is medicated from the 8th to 13th day of a period cycle, a second composition containing revonorgestral of 0.075mg and ethynyl estradiol of 0.04mg in daily dosage is medicated from 14th to 15th day, a third composition containing revonorgestral of 0.125mg and ethynyl estradiol of 0.03mg in daily dosage is medicated from 19th to 28th day.
摘要翻译：目的：提供口服避孕方法和组合物。某些组合物含有雄激素，优选甲睾酮，由避孕药具的年轻使用者服用，以抑制口服避孕药对骨矿物质密度的不利影响。构成：提供避孕药物的制剂，其含有雄激素，优选甲睾酮，孕激素和雌激素以改善避孕用具的骨矿物质密度。避孕配方使用三级以上的雄激素，根据使用者血清中睾酮水平的变化规定雄激素制剂。一方面，含有0.2-1.5mg的甲基睾酮，0.05mg的重新服用孕酮和每日剂量为0.03mg的乙炔基雌二醇的第一组合物从周期周期的第8至第13天进行药物治疗，第二组合物含有重新呼吸抑制剂0.075mg 日剂量为0.04mg的乙炔雌二醇为药物，第14〜15天为药物，日剂量为0.03mg的乙炔雌二醇含量为0.125mg，乙炔雌二醇为第三组，第19〜28d。

8. 发明授权

KR100232833B1 수정의 방지 또는 억제방법 失效
标题翻译：防止或抑制肥胖的方法
公开(公告)号：KR100232833B1
公开(公告)日：1999-12-01
申请号：KR1019950703491
申请日：1994-02-18
申请人： 헴프톤로드메디칼칼리지
发明人： 허드겐,그래이디이.
IPC分类号： A61K31/56
CPC分类号： A61K31/565 , Y10S514/01 , Y10S514/843
摘要： The use of a progesterone receptor antagonist for the preparation of a pharmaceutical composition for preventing an oocyte from becoming fertilized without preventing ovulation or interfering with the regularity of the ovarian menstrual cycle of a mammal.

9. 发明授权

KR100782638B1 에스트로겐 화합물 및 프로게스테론 화합물로 이루어진호르몬 조성물 有权
标题翻译：雌激素化合物和孕激素组合物的组成
公开(公告)号：KR100782638B1
公开(公告)日：2007-12-06
申请号：KR1020067013702
申请日：1997-10-08
申请人： 라보라뚜와르 떼라멕스
发明人： 랑끄땡,미쉘 , 빠리스,작끄 , 토마스,쟝-루이
IPC分类号： A61K38/22 , A61K31/57 , A61P15/18
CPC分类号： A61K45/06 , A61K31/56 , A61K31/565 , A61K31/57 , Y10S424/811 , Y10S514/841 , Y10S514/843 , A61K2300/00
摘要： 본 발명은 화학적 치료 분야, 특히 제약학적 호르몬 기술 분야에 관한 것이다. 더욱 상세하게, 본 발명은 에스트로겐 성분 및 프로게스테론 성분을 동시 투여할 수 있는 에스트로프로게스테론성 조합체가 불활성이며 비독성인 1종 이상의 약제학적으로 허용가능한 부형제와 배합되거나 혼합됨으로써 형성되어, 경구 방식으로 투여됨을 특징으로 하는 약제학적 에스트로프로게스테론성 조성물에 관한 것이다. 본 발명은 또한 에스트로겐 성분 및 프로게스테론 성분이 조합된 형태로 투여되는 에스트로프로게스테론성 조성물을 사용하는 방법에 관한 것이다. 폐경기 여성에게서 발생하는 에스트로겐 결핍의 치료, 골다공증 및 심장 혈관증의 예방, 또는 난소 활성 기간 동안에 여성의 배란 차단을 위해, 에스트로프로게스테론성 조성물은 연속적 또는 간헐적으로 투여될 수 있다. 본 발명은 또한 이러한 신규 에스트로프로게스테론성 조성물을 제조하는 방법에 관한 것이다.

10. 发明授权

KR100352571B1 배합호르몬피임약제 失效
公开(公告)号：KR100352571B1
公开(公告)日：2003-01-06
申请号：KR1019960705421
申请日：1995-03-30
申请人： 바이엘 파마 악티엔게젤샤프트
发明人： 라흐니트,우르술라 , 뒤스터베르그,베른트 , 스포나,위르겐
IPC分类号： A61K31/57 , A61K31/565
CPC分类号： A61K31/565 , A61K31/567 , A61K31/57 , Y10S514/843 , A61K2300/00
摘要： PCT No. PCT/EP95/01190 Sec. 371 Date Dec. 16, 1996 Sec. 102(e) Date Dec. 16, 1996 PCT Filed Mar. 30, 1995 PCT Pub. No. WO95/26730 PCT Pub. Date Oct. 12, 1995A pharmaceutical combination preparation with two hormone components that are manufactured physically separately in a packaging unit and that are intended for time-sequential oral administration, which in each case consist of a number of daily dosage units that are placed physically separately and are individually removable in the packaging unit. As a hormonal active ingredient, a first hormone component contains in combination an estrogen preparation and, in at least a dosage that is sufficient to inhibit ovulation, a gestagen preparation, and as a hormonal active ingredient the second hormone component contains only an estrogen preparation. The first hormone component comprises 23 or 24 daily units and the second hormone component comprises 4 to 10 daily units. The total number of hormone daily units is equal to the total number of days of the desired cycle, but at least 28 days in length. This combination preparation is used for female birth control, and allows for an estrogen content that is as low as possible in each individual dosage unit and also has a low total hormone content per administration cycle, with high contraceptive reliability, low incidence of follicular development, and satisfactory cycle control, with reliable avoidance of intracyclic menstrual bleeding as well as of undesirable side-effects.\!
摘要翻译： PCT No.PCT / EP95 / 01190 Sec。 371日期1996年12月16日 102（e）日期1996年12月16日PCT申请日1995年3月30日PCT Pub。 WO95 / 26730 PCT Pub。日期1995年10月12日具有两种激素成分的药物组合制剂，其在生理学上分开制造在包装单元中并且用于时间顺序口服给药，其在每种情况下由多个日常剂量单位组成，所述日剂量单位被物理分开并可在包装单元中单独拆卸。作为激素活性成分，第一种激素成分包含雌激素制剂和至少足以抑制排卵的剂量的孕激素制剂，并且作为激素活性成分，第二种激素成分仅包含雌激素制剂。第一个激素成分包含23或24个日常单位，第二个激素成分包含4到10个日常单位。激素每日单位的总数等于所需周期的总天数，但至少为28天。该组合制剂用于女性避孕，并允许每个单位剂量单位中的雌激素含量尽可能低，并且每个给药周期的总激素含量低，具有高避孕可靠性，卵泡发育的低发生率，以及令人满意的周期控制，可靠地避免周期性月经出血以及不良副作用。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式